We envision that the future of effective therapy for ovarian cancer will have to rely on (1) a combination of several therapies based on strong pre-clinical results and (2) a targeted approach based on the mutational background of the tumor (for example, HDAC6 inhibitor treatment of ARID1A mutated tumors). The gene discussed is ARID1A; the disease is neoplasm.